Alx oncology highlights differentiated design, preclinical data and development plans for egfr-targeted adc, alx2004, in r&d webcast event

- a potential best- and first-in-class antibody-drug conjugate (adc) for the treatment of egfr-expressing solid tumors, alx2004 is uniquely designed with every component optimized to maximize the therapeutic window by reducing toxicity

ALXO Ratings Summary

ALXO Quant Ranking